Briones-Garduño JC, Castillo-Henkel C, Skiold JL, Díaz DM

Language: Spanish
References: 25
Page: 489-494
PDF size: 68.44 Kb.

ABSTRACT

Background: Absence of innervation is a hallmark of human umbilical vessels. Intervillous space blood flow is regulated by vasoactive substances and calcium dependent contractility, both in normal and pathological conditions such as preeclampsia-eclampsia.
Objective: To obtain additional information on the intracellular calcium contractile effects of serotonin in human umbilical arteries.
Materials and Methods: Umbilical arteries from normal pregnancies were dissected, cut in 5 mm rings and mounted in a temperature-controlled isolated organ chamber, using calcium-free Krebs solution. The contractile effects of serotonin, lantane, verapamil and cyclopiazonic acid were evaluated at different concentrations using a computer coupled biopac polygraph.
Results: No differences in response were observed in the presence and absence of intracellular calcium. The positive contractile effects observed with serotonin were significantly decreased with repeated stimulation. An increase in the basal tone of the vessel was observed after calcium supplementation was added to the solution. This effect was minimized in the presence of verapamil and lantane. The contractile effects of serotonin in the calcium-free solution were not affected by the presence of cyclopiazonic acid.
Conclusions: Serotonin contractile effects in the human umbilical artery depend mainly on intracellular calcium levels which favor the gradual entrance of this ion over time. Calcium influx induced by serotonin is possible through L and Non-L channels apparently insensitive to ciclopiozonic acid.

REFERENCES

1. Abad A, Estaño L, Morales FJ, Serra V. Estudio de la contractilidad de los vasos coriónicos humanos in vitro en la preeclampsia. Prog Obstet Ginecol 2000;43:177-181.

2. 2. Briones GJC, Díaz de León PM, Gómez Bravo TE, Ávila EF, Briones VCG, Urrutia TF. Protocolo de manejo en la preeclampsia-eclampsia. Cirugía y Cirujanos 1999;67:6.

3. 3. Walsh MP. Regulation of vascular smooth muscle tone. Can J Physiol Pharmacol 1993;72:919-936.

4. 4. Minneman, KP, Esbenshade TA. a1 adrenergic receptor subtypes. Annu Rev Pharmacol Toxicol 1994;34:117-133.

5. 5. Martin GR. Vascular receptors for 5-hydroxytryptamine: distribution, function and classification. Pharmac Ther 1994;62:283-324.

6. 6. Fain JR, García-Sainz JA. Role of phosphatidylinositol turnover in a1 and of adenylate cyclase inhibition in a2 effects of catecholamines. Life Sci 1980;26:1183-1194.

7. 7. García-Sainz JA, Vázquez-Prado J, Villalobos-Molina R. a1-adrenoceptors: subtypes, signaling, and roles in health and disease. Arch Med Res 1999;30:449-458.

8. 8. Timmermans PB, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993;45:205-251.

9. 9. Suematsu E, Hirata M, Sasaguri T, Hashimoto T, Kuriyama H. Roles of Ca2+ on the inositol 1,4,5-triphosphate-induced release of Ca2+ from saponin-permeabilized single cells of the porcine coronary artery. Comp Biochem Physiol 1985;82:645-649.

10. Noguera MA, Ivorra MD, Chulia S, D´Ocon M P. Capacitative Ca2+ entry associated with a1-adrenoceptors in rat aorta. Naunyn Schmiedeberg´s Arch Pharmacol 1996;355:1-7.

11. Noguera MA, Madrero Y, Ivorra MD, D´Ocon P. Characterization of two different Ca2+ entry pathways dependent on depletion of internal Ca2+ pools in rat aorta. Naunyn-Schmiedeberg´s Arch Pharmacol 1998;357:92-99.

12. Terzic A, Puceat M, Vassort G, Vogel SM. Cardiac a1-adrenoceptors: an overview. Pharmacol Rev 1993;45:147-175.

13. Graham RM, Perez DM, Hwa J, Piascik MT. a1–Adrenergic receptor subtypes. Molecular structure, function and signaling. Circ Res 1996;78:737-49.

14. Varma DR, Deng X-F. Cardiovascular a1-adrenoceptor subtypes: functions and signaling. Can J Physiol Pharmacol 2000;78:267-292.

15. Karaki H, Ozaki H, Hori M, Mitsui-Saito M, Amano K, Harada K, et al. Calcium movements, distribution, and functions in smooth muscle. Pharmacol Rev 1997;49(No 2):157-230.

16. Putney JW. A model for receptor-regulated calcium entry. Cell Calcium 1986;7: 1-12.

17. Putney JW. Capacitative calcium.entry revisited . Cell Calcium 1990;11:611-634.

18. Felder CC, Singer-Lahat D, Mathes C. Voltage-independent calcium channels. Regulation by receptors and intracellular calcium stores. Biochem Pharmacol 1995;48:1997-2004.

19. Dessy C, Godfraind T. The effect of L-type calcium channel modulators on the mobilization of intracellular claim stores in guinea-pig intestinal smooth muscle. Br J Pharmacol 1996;119:142-148.

20. Asano M, Kuwako M, Nomura Y, Ito KM, Ito K, Uyama Y, et al. Possible mechanism of the potent vasoconstrictor actions of ryanodine on femoral arteries from spontaneously hypertensive rats. BrJ Pharmacol 1996;118:1019-27.

21. Noguera MA, D´Ocon MP. Evidence that depletion of internal calcium stores sensitive to noradrenaline elicits a contractile response dependent on extracellular calcium in rat aorta. Br J Pharmacol 1993; 110: 861-7.

22. Sekiguchi F, Shimamura K, Akashi M, Sunano S. Effects of cyclopiazonic acid and thapsigargin on electromechanical activities and intracellular Ca2+ in smooth muscle of carotid artery of hypertensive rats. Br J Pharmacol 1996; 118: 857-864.

23. Fasolato C, Innocenti B, Pozzan T. Receptor-activated Ca2+influx: how many mechanisms for how many channels? Trends Pharmacol Sci 1994;15:77-83.

24. Okoro EO. Overlap in the pharmacology of L-type Ca2+channel blockers and 5-HT2 receptor antagonists in rat aorta. J Pharm Pharmacol 1999; 51(8):953-957.

25. Gómez Bravo TE, Briones GJC, Morales EJG, Rodríguez RM. Mortalidad materna en el Estado de México. Rev Asoc Mex Med Crit y Ter Int 2003;17(6):199-203.